Predictive Role of Endoscopic Surveillance after Total Gastrectomy with R0 Resection for Gastric Cancer

Jung Su Lee; Jeong Hoon Lee; Jinyoung Kim; Hee Kyong Na; Ji Yong Ahn; Kee Wook Jung; Do Hoon Kim; Kee Don Choi; Ho June Song; Gin Hyug Lee; Hwoon-Yong Jung

doi:10.3346/jkms.2021.36.e88

Journal List > J Korean Med Sci > v.36(14) > 1146764

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lee, Lee, Kim, Na, Ahn, Jung, Kim, Choi, Song, Lee, and Jung: Predictive Role of Endoscopic Surveillance after Total Gastrectomy with R0 Resection for Gastric Cancer

Original Article

Gastroenterology & Hepatology

Journal of Korean Medical Science 2021; 36(14): e88.

Published online: 16 March 2021

DOI: https://doi.org/10.3346/jkms.2021.36.e88

Predictive Role of Endoscopic Surveillance after Total Gastrectomy with R0 Resection for Gastric Cancer

Jung Su Lee^1,²

, Jeong Hoon Lee¹

, Jinyoung Kim¹

, Hee Kyong Na¹

, Ji Yong Ahn¹

, Kee Wook Jung¹

, Do Hoon Kim¹

, Kee Don Choi¹

, Ho June Song¹

, Gin Hyug Lee¹

, Hwoon-Yong Jung¹

¹Division of Gastroenterology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

²Division of Gastroenterology, Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.

Address for Correspondence: Jeong Hoon Lee, MD, PhD. Division of Gastroenterology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. jhlee.gi@amc.seoul.kr

Received 27 October 2020 Accepted 20 January 2021

The Korean Academy of Medical Sciences

https://creativecommons.org/licenses/by-nc/4.0/

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Endoscopic surveillance after total gastrectomy (TG) for gastric cancer is routinely performed to detect tumor recurrence and postoperative adverse events. However, the reports on the clinical benefits of endoscopic surveillance are ambiguous. We investigated the clinical benefit of endoscopic surveillance after TG for gastric cancer.

Methods

We analyzed 848 patients who underwent TG with R0 resection for gastric cancer between 2011 and 2012 (380 early gastric cancer and 468 advanced gastric cancer) and underwent regular postoperative surveillance with endoscopy and abdominopelvic computed tomography (CT) with contrast.

Results

Median follow-up periods were 58 months for both endoscopy (range, 3–96) and abdominopelvic CT (range, 1–96). Tumor recurrence occurred in 167 patients (19.7%), of whom seven (4.2%) were locoregional recurrences in the peri-anastomotic area (n = 5) or regional gastric lymph nodes (n = 2). Whereas the peri-anastomotic recurrences were detected by both endoscopy and abdominopelvic CT, regional lymph node recurrences were only detected by abdominopelvic CT. Out of the 23 events of postoperative adverse events, the majority (87%) were detected by radiologic examinations; three events of benign strictures in the anastomotic site were detected only by endoscopy.

Conclusion

Endoscopic surveillance did not have a significant role in detecting locoregional tumor recurrence and postoperative adverse events after TG with R0 resection for gastric cancer. Routine endoscopic surveillance after TG may be considered optional and performed according to the capacities of each clinical setting.

Graphical Abstract

Keywords: Endoscopy, Surveillance, Gastric Cancer, Total Gastrectomy, Locoregional Recurrence, Postoperative Adverse Events

INTRODUCTION

Gastric cancer is one of the most important cancers in terms of global incidence and cancer-related deaths.1 In recent years, the overall outcome of gastric cancer has improved owing to increases in early detection by health screening programs and improvements in treatment modalities.2 3 4 5 The primary treatment for gastric cancer is curative R0 resection, but the clinical outcomes of radical gastrectomy with lymphadenectomy in patients with gastric cancer are occasionally poor due to tumor recurrence.6 As most cases of gastric tumor recurrence arise within 5 years after curative R0 resection,7 8 timely detection and resection of locoregional recurrences in the remnant gastric mucosa may be helpful in improving oncological outcomes.7 9 10

Regular endoscopic surveillance may be useful for early detection of locoregional recurrence in the remnant gastric mucosa.11 12 However, there is no remnant gastric mucosa after total gastrectomy (TG). Also, distant and/or peritoneal recurrences are more common than locoregional recurrence, and the prognosis for recurrent gastric cancer is poor despite treatment.7 13 14 15 Thus, it is controversial whether early detection of recurrence significantly prolongs overall survival, and there is no consensus on the strategies of follow-up period and methods, which currently rely on cohort and expert consensus rather than empirical data.16 17 18 19 20 Specifically, while there is no definite evidence on the clinical benefit of follow-up endoscopic surveillance after TG in terms of oncologic outcomes and detecting postoperative adverse events,15 21 annual follow-up endoscopic surveillance is performed in many clinical settings.

Therefore, we investigated the benefit of endoscopic surveillance in oncologic outcomes and detecting postoperative adverse events after TG for gastric cancer.

METHODS

Patients

We reviewed the medical records of all patients who underwent TG for gastric cancer between January 2011 and December 2012 at Asan Medical Center (Seoul, Korea). Of them, we analyzed 848 patients who also underwent surveillance every 6–12 months with regular endoscopy and abdominopelvic computed tomography (CT) with contrast after TG with R0 resection. All patients were observed until the detection of tumor recurrence or the last follow-up date of March 31, 2019. Gastric cancers were staged according to the 7th edition of the American Joint Committee on Cancer tumor node metastasis (TMN) classification.22 The tumors were classified into two types based on their histology-differentiated (well or moderately differentiated adenocarcinoma and papillary adenocarcinoma) and undifferentiated (poorly differentiated adenocarcinoma, signet ring cell, and mucinous adenocarcinoma). Patients were excluded according to the following criteria: follow-up loss within 1 year, second gastric resection for gastric cancer, other primary cancer diagnosed during surveillance, palliative TG, concomitant primary cancer, non-adenocarcinoma, TG with R1 resection, unevaluable pathology, operative mortality, therapeutic TG for postoperative adverse events, or history of organ transplantation (Fig. 1).

Fig. 1

Flowchart of patient enrollment and follow-up results.

TG = total gastrectomy, EGC = early gastric cancer, AGC = advanced gastric cancer.

Patterns of tumor recurrence

The patterns of tumor recurrence were categorized as locoregional, distant, peritoneal, and mixed.10 15 Locoregional recurrence included endoscopically accessible tumor recurrence (at the anastomotic site or within an intestinal loop) and endoscopically inaccessible tumor recurrence (dominant masses in the gastric bed or regional gastric lymph nodes). Distant recurrences were in specific organ sites or distant lymph nodes including para-aortic lymph nodes. Peritoneal recurrences included peritoneal seeding nodules on abdominopelvic CT and Krukenberg tumors. Mixed recurrences were defined as multiple recurrent sites at the initial recurrence episode.

Definition of benign stricture on esophagojejunal anastomotic area

We performed an endoscopic study for evaluating benign stricture on esophagojejunal (E-J) anastomotic area and used an endoscope with a maximal outer diameter of 9.8 mm (GIF-H260, Olympus Corp, Tokyo, Japan). We defined benign stricture on E-J anastomotic area as a narrowing without endoscopic passage, or with significant resistance for passage of endoscope, or with impacted food requiring endoscopic intervention in the esophagus.

Statistics

Categorical data were analyzed using the χ² test or Fisher's exact test as appropriate. Numerical data were analyzed using the Student's t-test. All statistical analyses were performed using the SPSS Statistics for Windows, version 18.0 (SPSS Inc., Chicago, IL, USA). P values < 0.05 were considered statistically significant.

Ethics statement

The Institutional Review Board of Asan Medical Center approved the study (IRB No. 2018-0561). Due to the retrospective study design, written informed consent was not obtained from participants. The IRB of our institution waived the need for informed consent based on the non-invasive and anonymized nature of this study. This study was conducted in accordance with institutional ethical guidelines and the Declaration of Helsinki.

RESULTS

Baseline characteristics of patients

The clinicopathological characteristics of the 848 patients are summarized in Table 1. Median age of the patients was 56 years (range, 18–79), and 549 (64.8%) were male. A total of 380 (44.8%) patients had early gastric cancer (EGC) and 468 (55.2%) had advanced gastric cancer (AGC). In 380 patients with EGC, 38 (10.0%) had multiple EGCs and the maximal number of synchronous EGCs in a patient was 6. In 468 patients with AGC, 17 (3.6%) patients had 2 synchronous gastric cancers and 7 (1.5%) patients had 3 synchronous gastric cancers. Eight patients who had gastric cancers in the lower third of the stomach received TG due to adhesion around the upper third of the stomach or severe metaplastic changes in the entire stomach.

Table 1

Baseline characteristics of the 848 patients who received TG for gastric cancer (n = 848)

Variables		Values
Age (median, range), yr		56 (18–79)
Sex (male:female)		549:299
Median follow-up period (median, range), mon
	Endoscopy	58 (3–96)
	Abdominopelvic CT	58 (1–96)
Site of tumor
	Upper third	430 (50.7)
	Middle third	323 (38.1)
	Lower third	8 (0.9)
	Entire	51 (6.0)
	Multiple	36 (4.2)
No. of tumors
	Single	786 (92.7)
	Multiple	62 (7.3)
Total lesion		931
Size of tumor (median, range), cm		4.5 (0.1–24)
Depth of invasion
	T1a	159 (18.8)
	T1b	221 (26.0)
	T2	99 (11.7)
	T3	221 (26.0)
	T4a	134 (15.8)
	T4b	14 (1.7)
Nodal metastasis
	N0	525 (61.9)
	N1	112 (13.2)
	N2	87 (10.3)
	N3	124 (14.6)
Stage
	IA	337 (39.7)
	IB	100 (11.8)
	IIA	108 (12.7)
	IIB	81 (9.6)
	IIIA	77 (9.1)
	IIIB	79 (9.3)
	IIIC	66 (7.8)
Histology
	Differentiated	263 (31.0)
	Undifferentiated	585 (69.0)

Data are the number of patients (%) unless otherwise noted.

TG = total gastrectomy, CT = computed tomography.

Follow-up and patterns of tumor recurrence

The distribution of patients according to the follow-up period and the patterns of tumor recurrence over time are shown in Fig. 2. Median time to follow-up was 58 months for both abdominopelvic CT (range, 1–96) and endoscopy (range, 3–96). In patients without tumor recurrence, 115 was followed up for less than 5 years; among these patients, 67 had EGC and 48 had AGC.

Fig. 2

The distribution of patients and patterns of recurrence over time. (A) The distribution of patients according to the follow-up period. (B) The patterns and timing of recurrence in the 167 patients. Values in the histogram represent the number of patients.

A total of 167 (19.7%) patients showed tumor recurrence. In 167 patients with tumor recurrence, 165 (98.8%) had AGC and only 2 (1.2%) had EGC. In 380 patients with EGC, tumor recurrence was very rare (0.5%). Median time of recurrence was 17 months (range, 1–88). Most (80.2%) of the tumor recurrence was confirmed within 3 years.

Two (1.2%) patients had EGCs: one of them showed locoregional recurrence in the E-J anastomotic area on endoscopy and abdominopelvic CT at 44 months after TG, and the other patient showed multiple bone metastases on abdominopelvic CT at 54 months after TG. The other 165 patients had AGCs, and the most common pattern of recurrence was peritoneal recurrence (n = 85, 51.5%). Distant recurrence, mixed recurrence, and locoregional recurrence occurred in 50 (30.3%), 24 (14.5%), and 6 cases (3.6%), respectively. In the mixed recurrence cases, the majority (n = 19, 79.2%) were both peritoneal and distant recurrence. Twelve (7.2%) of the 167 patients were confirmed to have tumor recurrence after 5 years. All recurrence cases were detected by abdominopelvic CT or other radiologic examinations.

Features of locoregional recurrence and the role of endoscopy

Locoregional recurrence was confirmed in 7 (0.8%) patients (Table 2). Of 7 locoregional recurrences, asymptomatic recurrences were 5 and symptomatic recurrences were 2. TG was performed in one of those patients for two synchronous EGCs and the other six patients for AGCs. Peri-anastomotic recurrence was found in five patients and recurrence in regional gastric lymph nodes in two patients. Importantly, all cases of peri-anastomotic recurrence were detected by both endoscopy and abdominopelvic CT (Fig. 3), and two cases of recurrence in regional lymph nodes were detected only by abdominopelvic CT. One case was considered to be clinically resectable at the initial episode of recurrence, but was found to be unresectable during laparotomy because of diaphragmatic invasion of the recurred tumor. Therefore, all cases of peri-anastomotic recurrence were unresectable in multidisciplinary discussion; the median survival time after recurrence was 12 months (range, 8–24 months). Two patients (patients #3 and #7 in Table 2) received conservative management without chemotherapy due to old age and poor performance status. The median recurrence-free survival time of patients with locoregional recurrence was 38 months (range, 10–55). The median recurrence-free survival time of cases with peri-anastomotic recurrence was longer than that of cases with other patterns of recurrence (38 vs. 16 months, P = 0.087).

Table 2

Summary of locoregional recurrences

Variables	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7
Sex/age	F/64	M/52	F/75	M/34	F/38	M/60	M/74
EGC/AGC	Two EGCs	AGC	AGC	AGC	AGC	AGC	AGC
Gross type	IIa + IIc/IIc	Borrmann IV	Borrmann III	Borrmann III	Borrmann IV	Borrmann II	Borrmann II
Tumor size, cm	4 × 3/2.7 × 2.3	9.5 × 7.3	4.3 × 3.7	4 × 3.2	20 × 18	4.5 × 4	7 × 5.6
Tumor location	Middle third/Middle third	Upper third	Upper third	Upper third	Entire	Middle third	Middle third
Tumor depth	SM3/M3	Subserosa	Subserosa	Subserosa	Muscularis propria	Subserosa	Subserosa
LN metastasis	No	Yes (nine)	Yes (one)	No	No	Yes (six)	Yes (one)
Histology	PD/PD	MD	PD	SRC	PD	PD	MD
LVI	No/No	Yes	No	Yes	No	Yes	No
PNI	Yes/No	Yes	Yes	Yes	Yes	Yes	No
Time interval from surgery to recurrence, mon	38	44	55	38	37	10	34
Related conditions	No	No	Vomiting, dyspepsia	Weight loss, dyspepsia	No	No	No
Recurrence site	E-J anastomotic area	Proximal part of E-loop	E-J anastomotic area	E-J anastomotic area	Proximal part of E-loop	LN at the splenic hilum	LN around celiac axis
Endoscopic findings	Mass	Nodularity	Ulcerative	Stricture	Nodularity	Non-specific finding	Non-specific finding
APCT findings	Asymmetric low attenuated wall thickening at the E-J anastomotic area	Ill-defined low-density mass in posterolateral aspect of E-J anastomotic area	Wall thickening with enhancement just distal to the E-J anastomotic area	Wall thickening with enhancement in E-J anastomotic area	Wall thickening with enhancement of jejunum below E-J anastomotic area	Lobulating contoured subtle low attenuating lesion around the splenic hilum	Lymphadenopathy around celiac axis
Treatment	O&C, CTx	CTx	Conservative	CTx	CTx	CTx	Conservative
Death	Yes	Yes	Yes	Yes	Yes	Yes	No
Time interval from surgery to death, mon	46	69	67	49	50	20	NA
Time interval from recurrence to death, mon	8	24	11	11	12	10	NA

EGC = early gastric cancer, AGC = advanced gastric cancer, SM = submucosa, M = mucosa, LN = lymph node, PD = poorly differentiate, MD = moderate differentiated, SRC = signet ring cell, LVI = lymphovascular invasion, PNI = perineural invasion, E-J = esophagojejunal, E-loop = efferent loop, APCT = abdominopelvic computed tomography, O&C = open and closure, CTx = chemotherapy, NA = not applicable.

Fig. 3

Endoscopic and contrast abdominopelvic CT findings of peri-anastomotic recurrence. The photos are each from patient #1 through patient #5 (left to right) in Table 2. (A) Mass of irregular shape around the anastomotic site. (B) Asymmetric low attenuated wall thickening at the anastomotic site. (C) Irregular nodularity with hyperemia on proximal part of the efferent loop. (D) Ill-defined low-density mass in the posterolateral aspect of the anastomotic site. (E) Irregular ulcerative lesion with luminal narrowing at the anastomotic site. (F) Wall thickening with enhancement just distal to the E-J anastomotic area. (G) Stricture of the anastomotic site with irregular mucosal nodularity. (H) Wall thickening with enhancement in the anastomotic site. (I) Irregular nodularity with hyperemia on the proximal part of the efferent loop. (J) Wall thickening with an enhancement of jejunum below the anastomotic site.

CT = computed tomography, E-J = esophagojejunal.

Postoperative adverse events based on endoscopic and radiologic findings

A total of 23 postoperative adverse events were observed in 21 (2.5%) patients (Table 3): 17 events were detected only by radiologic study, 3 were detected only by endoscopic study, and 3 were detected by both endoscopic and radiologic studies. Three cases of benign stricture in the anastomotic site were detected only by endoscopic evaluation. The clinical and endoscopic features are summarized in Table 4. One patient who received surgical repair for anastomotic leakage at 10 days after TG underwent endoscopic removal of impacted food at 70 months after TG. Additional treatments for benign stricture were not recommended. Because even though the anastomotic site was narrow, endoscopic passage through the narrowing anastomotic site was possible and the patient did not complain of dysphagia except for the endoscopic intervention of impacted food in the esophagus. Another patient had the anastomotic site narrowing with endoscopic passage. Interventional treatments were not recommended because of the absence of dysphagia. The other patient had severe anastomotic site narrowing without endoscopic passage and had strangulation in the small bowel. The patient had received surgical treatment for benign stricture and strangulation in the small bowel. Anastomotic leakage and leakage at blind end of the jejunum in three patients were detected by radiologic study and treated by endoscopic closure with a clip. Anastomotic leakage in one patient was detected by radiologic study and treated by surgical repair.

Table 3

Endoscopic and radiologic findings of postoperative adverse events

Postoperative adverse events			No.
Total			23
Detected by radiology			20
	Ileus		11
		Mechanical	8
		Paralytic	1
		Strangulation	2
	Intra-abdominal abscess		3
	Intra-abdominal bleeding		1
	Intussusception		1
	Anastomotic leakage		1
Detected by endoscopy			3
	Anastomotic stricture		3
Detected by both radiology and endoscopy			3
	Anastomotic leakage		2
	Leakage at the blind end of the jejunum		1

Table 4

Clinical and endoscopic features of benign stricture on esophagojejunal anastomotic area

Variables	Patient A	Patient B	Patient C
Sex/age	M/60	M/46	M/68
EGC/AGC	AGC	AGC	EGC
Tumor size, cm	5 × 4.6	2 × 1.5	5.7 × 3.5
Tumor location	Upper third	Upper third	Upper third
Proximal resection margin, cm	0.8	2	2.1
Distal resection margin, cm	11	13	10.2
Time interval from surgery to benign stricture, mon	70	16	12
Related conditions	Impacted food in esophagus	Dysphagia	None
Endoscopic passage	Yes, with significant resistance	No	Yes, with significant resistance
Clavien–Dindo classification	IIIa	IIIb	II

EGC = early gastric cancer, AGC = advanced gastric cancer.

DISCUSSION

In our study, 848 patients received total gastrectomy with R0 resection for gastric cancer and only seven (0.8%) of them had locoregional recurrence. Specifically, five cases (0.5%) of peri-anastomotic recurrence were detected by both endoscopy and abdominopelvic CT, and two cases of recurrence in regional lymph nodes were detected only by abdominopelvic CT. The majority (87%) of the postoperative adverse events were detected by radiologic examinations, and only 3 events of benign strictures were detected only by endoscopy.

Many guidelines for gastric cancer recommended endoscopic surveillance for detecting local recurrence after gastrectomy. In Japanese guidelines, biannual endoscopic surveillance is recommended for detecting recurrence from the first year after gastrectomy.23 Similarly, Chinese guidelines recommend annual endoscopic surveillance after gastrectomy regardless of EGC or AGC.24 In Italian guidelines, a follow-up strategy based on the risk of recurrence is recommended including annual endoscopy except at 48 months.25 26 Nevertheless, the guidelines also mention that the recommendation for routine endoscopic surveillance lacks sufficient empirical evidence.23 24 25 The Korean guidelines for gastric cancer do not specifically mention the need for surveillance programs after gastrectomy27; however, survey results from the Korean Gastric Cancer Association showed that physicians perform regular surveillance every 6–12 months and that endoscopy is frequently performed.28

However, many guidelines for gastric cancer recommended endoscopic surveillance after gastrectomy regardless of gastrectomy types including TG and subtotal gastrectomy (STG). It is a need to distinguish between TG and STG, because of the remnant gastric mucosa. Endoscopic surveillance for STG can detect metachronous gastric cancer in remnant gastric mucosa not only locoregional recurrence. Han et al.29 recommended annual endoscopic surveillance for remnant gastric cancer up to 20 years after STG. Also, several studies reported that endoscopic surveillance was significantly helpful in detecting locoregional recurrence including metachronous gastric cancer in remnant gastric mucosa and associated with improvement of oncologic outcome after secondary gastric resection or endoscopic submucosal dissection.9 11 12 30 31 32 33 34 35 However, there is no remnant gastric mucosa after TG. In our study, peri-anastomotic recurrence were rare (0.5%) and detected by both endoscopy and abdominopelvic CT. Endoscopic surveillance after TG may be considered optional according to the capacities of each clinical setting.

Recent studies reported low incidences (1.6%–1.8%) of locoregional recurrence after TG for gastric cancer due to the absence of remnant gastric mucosa.36 37 Also, recurred tumors were frequently unresectable and associated with poor prognosis.15 34 38 In our results, only 7 out of 848 (0.8%) patients who underwent TG with R0 resection for gastric cancer cases were confirmed to have locoregional recurrence. All cases of locoregional recurrence were uncurable due to unresectable or poor performance status.

All seven cases of locoregional recurrence including peri-anastomotic area and regional gastric lymph node were detected by abdominopelvic CT; in contrast, endoscopy could not detect the two cases of recurrence in regional lymph nodes. Also, radiologic examinations including abdominopelvic CT successfully detected all recurrence cases. Collectively speaking, regular endoscopic surveillance had limited benefit over radiologic study for detecting locoregional recurrence after TG for gastric cancer.

Peri-anastomotic recurrence is assumed to occur from submucosal or subserosal lymphatics spread of cancer cells or the implantation of exfoliated cancer cells.39 40 41 Therefore, peri-anastomotic recurrence may be due to tumor invasion from the outer layer of the lumen. Abnormality of the inner layer of the lumen can only be detected by endoscopy. In our results, radiologic findings of peri-anastomotic recurrence were bowel wall thickening or mass. Therefore, endoscopy may be limited in the early detection of peri-anastomotic recurrence.

The other role of regular endoscopic surveillance after TG is to detect postoperative adverse events, especially anastomotic strictures. Lee et al.15 reported that the incidence of benign stricture at anastomosis site was 7% and suggested that routine follow-up endoscopy after TG for gastric cancer was useful in the early detection and treatment for benign strictures. In more recent studies, the incidence of anastomotic stricture after TG for gastric cancer was reported to be as low as 0.9%–2.0%.42 43 In our study, only 3 out of 848 (0.4%) patients had anastomotic site narrowing during endoscopy. Only one patient underwent endoscopic removal of food stasis. Because endoscopy passage through the narrowing anastomotic site was possible, no additional endoscopic intervention was necessary. Thus, in our data, the role of regular endoscopic surveillance for postoperative adverse events was also largely inconsequential due to the low incidence and severity.

Some methodological limitations of this study should be noted. First of all, our study design is retrospective and observational in nature. However, it is difficult to conduct a randomized controlled trial on postoperative surveillance programs because of the follow-up period, number of patients, and ethical issues. Therefore, many reviews for surveillance after gastrectomy for gastric cancer were based on retrospective observational studies.44 45 46 To compensate for the innate weakness of such study design, we analyzed a large number of patients who were treated within a relatively recent period and followed for over 5 years. Whereas recent studies on a similar topic15 21 each studied a total of 212 and 70 patients, we analyzed a total of 380 EGC patients. The second limitation is the rarity of locoregional recurrence. We tried to determine the risk factors of locoregional recurrence, especially peri-anastomotic recurrence, because such patients may benefit from early detection of peri-anastomotic recurrence and additional surgical treatment. However, locoregional recurrence was rare (0.8%) and statistical analysis was not feasible. The third limitation is the absence of information about adverse events of endoscopy and radiologic study. In many guidelines, regular endoscopic and radiologic surveillance will be performed 3–5 times per patient for 5 years. Major adverse events of endoscopy and radiologic study are rare, but it can be life-threatening.47 48 Therefore, the necessity of regular surveillance with endoscopy and radiologic study will be considered with possibilities of endoscopic and radiologic study induced adverse events. Further studies are needed about the clinical benefit and risk of regular surveillance. Finally, we did not consider the types of TG based on open and laparoscopy. Because laparoscopic TG (LTG) was a technical difficulty, especially the reconstruction of the E-J, it is a clinically important concern for surgical and oncologic outcomes. The recent studies reported that the surgical and oncologic outcomes of LTG were feasible and safe compared with open TG.42 43 A few meta-analyses for outcomes based on surgical types reported that the short-term outcomes were similar or feasible in LTG compared with open TG.49 50 However, the long-term outcomes were inconclusive, because these studies were enrolled in a relatively small number and single-center study. The long-term outcomes including locoregional recurrence and benign stricture in the anastomotic site are important to consider endoscopic surveillance. So, further studies with large, multi-center study are needed for these concerns.

In conclusion, locoregional recurrence and anastomotic strictures after TG were rare, and endoscopic surveillance after TG with R0 resection for gastric cancer did not show a significant benefit over abdominopelvic CT in detecting tumor recurrence or postoperative adverse events. Routine endoscopic surveillance after TG may be considered optional and performed according to the capacities of each clinical setting.

Notes

Disclosure: The authors have no potential conflicts of interest to disclose.

Author Contributions:

Conceptualization: Lee JH, Lee JS, Kim JY.
Data curation: Lee JS, Kim JY.
Formal analysis: Lee JH, Lee JS.
Investigation: Kim DH, Song HJ, Jung HY.
Methodology: Choi KD, Lee GH.
Software: Lee JS.
Validation: Na HK, Ahn JY, Jung KW.
Writing - original draft: Lee JS.
Writing - review & editing: Lee JH.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394–424. PMID: 30207593.

2. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, et al. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014; 50(7):1330–1344. PMID: 24650579.

3. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004; 291(2):187–194. PMID: 14722144.

4. Park HA, Nam SY, Lee SK, Kim SG, Shim KN, Park SM, et al. The Korean guideline for gastric cancer screening. J Korean Med Assoc. 2015; 58(5):373–384.

5. Hamashima C, Shibuya D, Yamazaki H, Inoue K, Fukao A, Saito H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol. 2008; 38(4):259–267. PMID: 18344316.

6. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016; 388(10060):2654–2664. PMID: 27156933.

7. Nakagawa M, Kojima K, Inokuchi M, Kato K, Sugita H, Kawano T, et al. Patterns, timing and risk factors of recurrence of gastric cancer after laparoscopic gastrectomy: reliable results following long-term follow-up. Eur J Surg Oncol. 2014; 40(10):1376–1382. PMID: 24915857.

8. Spolverato G, Ejaz A, Kim Y, Squires MH, Poultsides GA, Fields RC, et al. Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. J Am Coll Surg. 2014; 219(4):664–675. PMID: 25154671.

9. Lehnert T, Rudek B, Buhl K, Golling M. Surgical therapy for loco-regional recurrence and distant metastasis of gastric cancer. Eur J Surg Oncol. 2002; 28(4):455–461. PMID: 12099659.

10. Pak KH, Hyung WJ, Son T, Obama K, Woo Y, Kim HI, et al. Long-term oncologic outcomes of 714 consecutive laparoscopic gastrectomies for gastric cancer: results from the 7-year experience of a single institute. Surg Endosc. 2012; 26(1):130–136. PMID: 21789641.

11. Hosokawa O, Kaizaki Y, Watanabe K, Hattori M, Douden K, Hayashi H, et al. Endoscopic surveillance for gastric remnant cancer after early cancer surgery. Endoscopy. 2002; 34(6):469–473. PMID: 12048630.

12. Jang HJ, Choi MH, Shin WG, Kim KH, Baek IH, Kim KO, et al. Is annual endoscopic surveillance necessary for the early detection of gastric remnant cancer in Korea? A retrospective multi-center study. Hepatogastroenterology. 2014; 61(133):1283–1286. PMID: 25436297.

13. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006; 24(31):4991–4997. PMID: 17075117.

14. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687–697. PMID: 20728210.

15. Lee SY, Lee JH, Hwang NC, Kim YH, Rhee PL, Kim JJ, et al. The role of follow-up endoscopy after total gastrectomy for gastric cancer. Eur J Surg Oncol. 2005; 31(3):265–269. PMID: 15780561.

16. Bilici A, Salman T, Oven Ustaalioglu BB, Unek T, Seker M, Aliustaoglu M, et al. The prognostic value of detecting symptomatic or asymptomatic recurrence in patients with gastric cancer after a curative gastrectomy. J Surg Res. 2013; 180(1):e1–9. PMID: 22520575.

17. Peixoto RD, Lim HJ, Kim H, Abdullah A, Cheung WY. Patterns of surveillance following curative intent therapy for gastroesophageal cancer. J Gastrointest Cancer. 2014; 45(3):325–333. PMID: 24756830.

18. Park CH, Park JC, Chung H, Shin SK, Lee SK, Cheong JH, et al. Impact of the surveillance interval on the survival of patients who undergo curative surgery for gastric cancer. Ann Surg Oncol. 2016; 23(2):539–545. PMID: 26424325.

19. Eom BW, Ryu KW, Lee JH, Choi IJ, Kook MC, Cho SJ, et al. Oncologic effectiveness of regular follow-up to detect recurrence after curative resection of gastric cancer. Ann Surg Oncol. 2011; 18(2):358–364. PMID: 21042946.

20. Cardoso R, Coburn NG, Seevaratnam R, Mahar A, Helyer L, Law C, et al. A systematic review of patient surveillance after curative gastrectomy for gastric cancer: a brief review. Gastric Cancer. 2012; 15(Suppl 1):S164–S167. PMID: 22382929.

21. Park SJ, Park YS, Jung IS, Yoon H, Shin CM, Ahn SH, et al. Is endoscopic surveillance necessary for patients who undergo total gastrectomy for gastric cancer? PLoS One. 2018; 13(6):e0196170. PMID: 29856747.

22. Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010; 17(12):3077–3079. PMID: 20882416.

23. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021; 24(1):1–21. PMID: 32060757.

24. Wang FH, Shen L, Li J, Zhou ZW, Liang H, Zhang XT, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (Lond). 2019; 39(1):10. PMID: 30885279.

25. De Manzoni G, Marrelli D, Baiocchi GL, Morgagni P, Saragoni L, Degiuli M, et al. The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015. Gastric Cancer. 2017; 20(1):20–30.

26. Baiocchi GL, Kodera Y, Marrelli D, Pacelli F, Morgagni P, Roviello F, et al. Follow-up after gastrectomy for cancer: results of an international web round table. World J Gastroenterol. 2014; 20(34):11966–11971. PMID: 25232232.

27. Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean practice guideline for gastric cancer 2018: an evidence-based, multi-disciplinary approach. J Gastric Cancer. 2019; 19(1):1–48. PMID: 30944757.

28. Hur H, Song KY, Park CH, Jeon HM. Follow-up strategy after curative resection of gastric cancer: a nationwide survey in Korea. Ann Surg Oncol. 2010; 17(1):54–64. PMID: 19777193.

29. Han ES, Seo HS, Kim JH, Lee HH. Surveillance endoscopy guidelines for postgastrectomy patients based on risk of developing remnant gastric cancer. Ann Surg Oncol. 2020; 27(11):4216–4224. PMID: 32372310.

30. Greene FL. Management of gastric remnant carcinoma based on the results of a 15-year endoscopic screening program. Ann Surg. 1996; 223(6):701–706. PMID: 8645043.

31. Fujita T, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kinoshita T. Relationship between the histological type of initial lesions and the risk for the development of remnant gastric cancers after gastrectomy for synchronous multiple gastric cancers. World J Surg. 2010; 34(2):296–302. PMID: 20012285.

32. Ohashi M, Katai H, Fukagawa T, Gotoda T, Sano T, Sasako M. Cancer of the gastric stump following distal gastrectomy for cancer. Br J Surg. 2007; 94(1):92–95. PMID: 17054314.

33. Na HK, Ahn JY, Lee JH, Kim DH, Choi KD, Song HJ, et al. Clinical outcomes of recurrent gastric cancer detected by upper endoscopy after curative total gastrectomy. Tumori. 2017; 103(2):164–169. PMID: 27841437.

34. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000; 87(2):236–242. PMID: 10671934.

35. Barakat M, Seif M, Abdelfatah MM, Ofosu A, Carr-Locke DL, Othman MO. Endoscopic submucosal dissection for early neoplastic lesions in the surgically altered stomach: a systematic review and meta-analysis. Surg Endosc. 2019; 33(8):2381–2395. PMID: 30963259.

36. Yoo CH, Sohn BH, Han WK, Pae WK. Long-term results of proximal and total gastrectomy for adenocarcinoma of the upper third of the stomach. Cancer Res Treat. 2004; 36(1):50–55. PMID: 20396565.

37. Jeong GA, Cho GS, Kim HH, Lee HJ, Ryu SW, Song KY. Laparoscopy-assisted total gastrectomy for gastric cancer: a multicenter retrospective analysis. Surgery. 2009; 146(3):469–474. PMID: 19715803.

38. Bar-Sela G, Tsalic M, Steiner M, Wollner M, Haim N. Local recurrence following adjuvant chemotherapy without radiotherapy in completely resected stomach and gastroesophageal junction adenocarcinoma. Anticancer Res. 2009; 29(5):1853–1856. PMID: 19443416.

39. Papachristou DN, Karas M, Fortner JG. Anastomotic recurrence in the oesophagus complicating gastrectomy for adenocarcinoma of the stomach. Br J Surg. 1979; 66(9):609–612. PMID: 497643.

40. Nishimura M, Honda I, Watanabe S, Nagata M, Souda H, Miyazaki M. Recurrence in jejunal pouch after proximal gastrectomy for early upper gastric cancer. Gastric Cancer. 2003; 6(3):197–201. PMID: 14520535.

41. Namikawa T, Kobayashi M, Okamoto K, Okabayashi T, Akimori T, Sugimoto T, et al. Recurrence of gastric cancer in the jejunal pouch after completion gastrectomy. Gastric Cancer. 2007; 10(4):256–259. PMID: 18095082.

42. Lee MS, Lee JH, Park DJ, Lee HJ, Kim HH, Yang HK. Comparison of short- and long-term outcomes of laparoscopic-assisted total gastrectomy and open total gastrectomy in gastric cancer patients. Surg Endosc. 2013; 27(7):2598–2605. PMID: 23539255.

43. Kim HS, Kim BS, Lee IS, Lee S, Yook JH, Kim BS. Comparison of totally laparoscopic total gastrectomy and open total gastrectomy for gastric cancer. J Laparoendosc Adv Surg Tech A. 2013; 23(4):323–331. PMID: 23379920.

44. D'Ugo D, Biondi A, Tufo A, Persiani R. Follow-up: the evidence. Dig Surg. 2013; 30(2):159–168. PMID: 23867593.

45. Aurello P, Petrucciani N, Antolino L, Giulitti D, D'Angelo F, Ramacciato G. Follow-up after curative resection for gastric cancer: is it time to tailor it? World J Gastroenterol. 2017; 23(19):3379–3387. PMID: 28596674.

46. Nilsson M. Postgastrectomy follow-up in the West: evidence base, guidelines, and daily practice. Gastric Cancer. 2017; 20(Suppl 1):135–140. PMID: 27718134.

47. Bettmann MA, Heeren T, Greenfield A, Goudey C. Adverse events with radiographic contrast agents: results of the SCVIR Contrast Agent Registry. Radiology. 1997; 203(3):611–620. PMID: 9169677.

48. ASGE Standards of Practice Committee. Ben-Menachem T, Decker GA, Early DS, Evans J, Fanelli RD, et al. Adverse events of upper GI endoscopy. Gastrointest Endosc. 2012; 76(4):707–718. PMID: 22985638.

49. Best LM, Mughal M, Gurusamy KS. Laparoscopic versus open gastrectomy for gastric cancer. Cochrane Database Syst Rev. 2016; 3(3):CD011389. PMID: 27030300.

50. Haverkamp L, Weijs TJ, van der Sluis PC, van der Tweel I, Ruurda JP, van Hillegersberg R. Laparoscopic total gastrectomy versus open total gastrectomy for cancer: a systematic review and meta-analysis. Surg Endosc. 2013; 27(5):1509–1520. PMID: 23263644.

TOOLS

Similar articles